2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
44
Lung Neoplasms
9
Brain Neoplasms
7
NSCLC
4
Pancreatic Neoplasms
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Esophageal Neoplasms
2
EGF-R Positive Non-Small Cell Lung Cancer
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Squamous Cell Carcinoma of Lung
1
Plasma EGFR Mutation-positive Lung Cancer
1
Non-squamous Non-small Cell Lung Cancer
1
Non-small Cell Lung Cancer Metastatic
1
Non-Small-Cell Lung
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms, Second Primary
1
Neoplasm Metastasis
1
Drug-Related Side Effects and Adverse Reactions
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
Bevacizumab
6
Everolimus
4
Sirolimus
2
Lapatinib
2
HDAC-42
2
vistusertib
1
temsirolimus
1
neratinib
1
icotinib
1
emvododstat
1
brolucizumab
1
brigatinib
1
aflibercept
1
Vascular Endothelial Growth Factor A
1
Valproic Acid
1
Sunitinib
1
Magnetic Resonance Imaging
1
Immunoglobulin G
1
Exome
1
Endostatins
1
Doxycycline
1
Disulfides
1
Crizotinib
1
Cetuximab
1
Axitinib
1
Aspirin
1
AZD 6244
1
89Zr-bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neurofibromatosis 2
×
icotinib
×
Clear all
NCT02934256
2021-09-09
Icotinib
Beijing Tiantan Hospital
Phase 2
Completed
10 enrolled